Skip to Main content Skip to Navigation
Master Thesis

Amélioration de la survie globale des patients porteurs de cancer du rein métastatique grâce aux thérapies ciblées‎ : revue monocentrique depuis 2000

Abstract : Introduction: Anti-angiogenic treatment had radically modified therapeutic strategy in metastatic renal cell carcinoma (mRCC). This study is aimed to determine the overall survival (OS) improvement in clinical practice. Patients and methods: Retrospective, monocentric and non-interventional study in mRCC diagnosed since 2000 with 2 cohorts of patients determined according to the first line treatment (targeted therapy or others treatment). Results: Between 1 January 2000 and 31 December 2010, 98 patients were included. The 2 cohorts were balanced with regard to baseline disease and demographic characteristics in particular for prognosis profiles distribution. As first line, 58 patients received targeted therapy whose 21% were treated by bevacizumab, 71% by sunitinib and 8% by temsirolimus. In non-targeted therapy cohort (n=40), 37.5% were treated by cytokines, 15% by cytotoxic chemotherapy or hormonal therapy. Patients treated with targeted therapy had a significantly longer median OS (30 months vs 13 months; p < .003, log-rank test). The Hazard Ratio (HR) of death at 3 years was 0.53 (95% Confidence Interval, 0.33-0.85; p=.008, log-rank test). When adjusted to the prognosis profile, the HR of death was 0.43 (95%CI, 0.27-0.71). Conclusions: This retrospective study demonstrated the improvement of OS due to targeted treatments, for all prognostic risk groups. This result supported the complete change of care of mRCC patients with extension of therapeutic indications and efficient therapeutic lines.
Document type :
Master Thesis
Complete list of metadata

Cited literature [17 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-00824923
Contributor : Jean-Hugues Morneau <>
Submitted on : Wednesday, May 22, 2013 - 3:49:54 PM
Last modification on : Tuesday, May 11, 2021 - 11:36:16 AM
Long-term archiving on: : Friday, August 23, 2013 - 4:11:22 AM

Identifiers

  • HAL Id : dumas-00824923, version 1

Citation

Mélanie Tadj. Amélioration de la survie globale des patients porteurs de cancer du rein métastatique grâce aux thérapies ciblées‎ : revue monocentrique depuis 2000. Médecine humaine et pathologie. 2013. ⟨dumas-00824923⟩

Share

Metrics

Record views

236

Files downloads

361